DIRS.INFO The most relevant business & tech news

☆ A Gen Z diabetic said a 3-month supply of insulin pumps would cost her $1,800 — even with insurance
▼ + stars: | 2024-02-03 | by ( Allie Kelly | ) www.businessinsider.com time to read: +7 min

However, others, like 25-year-old Cochrin, are still seeking some relief for the costs of insulin and other necessary diabetes tools, like insulin pumps and continuous glucose monitors. While the costs of insulin have skyrocketed, and the direct medical costs of treating diabetes have also increased by about 7% since 2017. AdvertisementEarlier this month, Cochrin posted a TikTok explaining that a 3-month supply of her insulin pumps would cost her $1,800, even after insurance. Her continuous glucose monitor doesn't cost her anything right now, but in the past, she paid $30 a month with insurance. AdvertisementDifferent people may have increased sensitivity to different types and brands of insulin, Cochrin said, but insurance companies sometimes only offer one option for coverage.

Persons: —, Grace Cochrin's, Joe Biden, Eli Lilly, Sanofi, it's, Cochrin, She's, Campbell Hutton Organizations: Service, American Diabetes Association, National Institutes of Health, Business, White, US Department of Health, Human Services, that's Locations: Charlotte, North Carolina

☆ FDA panel to examine ways to better evaluate pulse oximeters for skin color bias
▼ + stars: | 2024-02-02 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +6 min

CNN —The longstanding problem of pulse oximeters providing less-accurate readings for people with dark skin tones is getting another look from a panel of experts for the US Food and Drug Administration. The FDA’s Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee is meeting Friday to review ways to better evaluate the accuracy and performance of pulse oximeters in patients with darker skin. Pulse oximeters are fingertip clamps that send light beams through your finger to estimate the oxygen saturation of your blood and your pulse rate. “That standard is then applied to all people as a one-size-fits-all, but time and again, we have seen in medicine that this approach leads to poor outcomes for certain groups, especially Black patients,” Ibekie said. “We need to address the root and work harder to conduct research with patients that represent our populations as a whole,” she said.

Persons: Dionne Ibekie, “, Ibekie, ”, ” Ibekie, “ I’m, Leo Anthony Celi, ” Celi, White, Dr, Sanjay Gupta Organizations: CNN, US Food and Drug Administration, Medical Devices, FDA, MIT Laboratory, Computational Physiology, MIT Institute for Medical Engineering, Science, Genomics, CNN Health Locations: Illinois

☆ Neuralink competitor Synchron to ramp up brain implant production with equity stake in manufacturer
▼ + stars: | 2024-02-01 | by ( Ashley Capoot | In | ) www.cnbc.com time to read: +2 min

Philip O'Keefe, one of Synchron's patients in the SWITCH clinical trial, was the first person in the world to tweet using a BCI device. Synchron announced Thursday that it has acquired a minority equity stake in the German manufacturer Acquandas, which has the unique ability to layer the metals that make up one component of the company's implant. Founded in 2012, Synchron has developed a brain-computer interface, or a BCI, called the Synchron Switch. During initial studies, Synchron has so far implanted six patients in the U.S. and four patients in Australia. Synchron declined to share the specific size of Synchron's stake in Acquandas or the exact number of devices it is producing.

Persons: Philip O'Keefe, Synchron, Tom Oxley, Riki Banerjee, Oxley, Acquandas Organizations: BCI, U.S . Food, Drug Administration, CNBC Locations: U.S, Australia, Acquandas

☆ We're calling up a health care stock from our Bullpen watch list, starting a new position
▼ + stars: | 2024-01-29 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

Shortly after the opening bell, we're initiating a position in Abbott Laboratories (ABT), buying 275 shares at roughly $112 each. The way Abbott's stock has traded, it's acted like GLP-1s were a cure and people would no longer need these devices. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

Persons: Jim Cramer's, Abbott, Novo's, it's, Eli Lilly, we're, We're, Alinity, Abbott isn't, Jim Cramer, Jim Organizations: Abbott Laboratories, ABT, Jim Cramer's Charitable, Abbott, Novo Nordisk, Nutrition, JPMorgan, Pharmaceuticals, Core, GLP, Diagnostics, CNBC Locations: United States, LLY

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
▼ + stars: | 2024-01-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged. J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. The pharmaceutical giant reported net income of $4.13 billion, or $1.70 per share during the quarter. J&J is now zeroing in on its pharmaceutical and medical devices divisions to drive growth.

Persons: Johnson, J Organizations: LSEG

☆ 'A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks
▼ + stars: | 2024-01-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

2023 wasn't a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. But now, Citi believes that "astute investors may find themselves with a trove of rebound opportunities." Citi's top picks in biotech include Biomea Fusion , Alnylam Pharmaceuticals , and Immunovant . Jared Holz, health-care sector strategist at Mizuho Securities Americas, named biotech firm Biogen as one of his top trading ideas for 2024. "Biotech has commanded everyone's attention, but the recovery of many best-in-class medical device companies post the GLP-1 selloff has been remarkable," Orton said.

Persons: There's, Jared Holz, Biogen, Trent, medtech, Matt Orton, Orton Organizations: Citi Global Wealth Investments, U.S . Healthcare, Citi, Biomea, Alnylam Pharmaceuticals, Mizuho Securities Americas, Biogen, medtech, Raymond James Investment Management, Medical, Biotech, Abbott Laboratories Locations: U.S, Alphinity, medtech

☆ 2 boomers from Chicago who bought homes in Florida share why they're retiring in the Sunshine State — and what they miss about Illinois
▼ + stars: | 2024-01-13 | by ( Noah Sheidlower | ) www.businessinsider.com time to read: +9 min

Two boomers who are moving to Florida for retirement say the state meets their retirement goals. The Illinois to Florida move in particular was one of the largest US migration patterns between 2021 and 2022. Daniel Mehalek, 61Daniel Mehalek, 61, lived in the Chicago area his whole life. Compared to Chicago, he's paying more on flood, homeowner's, and car insurance in Florida, though it's offset by the over $15,000 in Illinois state taxes he won't have to pay when he relocates. "Insurance is a challenge right now, but I still feel like that's a better situation overall than being in Illinois and paying the property and state taxes," Ron said.

Persons: boomer, —, It's, hasn't, Daniel Mehalek, He's, Mehalek, I'm, Florida hasn't, Ron, he's Organizations: Service, Sunshine State, Business, Chicago, Fortune, Boeing, Citadel, Caterpillar, Illinois, Sarasota Locations: Florida, New York , California , New Jersey, Georgia, Illinois, The Illinois, Georgia , Texas, North Carolina, Chicago, Burr, California, Bonita Springs, Naples —, Wisconsin, Sarasota, New Jersey, Tampa Bay

☆ US FDA Identifies Recall of ResMed's Respiratory Devices as Most Serious
▼ + stars: | 2024-01-11 | by ( Jan. | At P.M. | ) www.usnews.com time to read: +1 min

(Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death. ResMed was recalling some models of its continuous positive airway pressure (CPAP) masks, AirFit and AirTouch, due to possible magnetic interference with certain medical devices and implants which might disrupt their function or position and cause serious harm or death, the FDA said. The FDA said ResMed was recalling these masks to update the labels and add more warnings and information. The California-based medical device maker started the recall process on Nov. 20 and has recalled over 20 million devices in the United States. The health regulator said there has been six reported injuries and no reports of death due to the devices.

Persons: ResMed, Mariam Sunny, Maju Samuel Organizations: Reuters, U.S . Food, Drug Administration, FDA Locations: U.S, California, United States, Bengaluru

☆ AI, wearables and more — these markets are booming as the world ages. The pros share 4 stock picks
▼ + stars: | 2023-12-27 | by ( Weizhen Tan | ) www.cnbc.com time to read: +6 min

"The aging population discussion in recent years has mostly revolved around future challenges to labor productivity and its economic growth implications," he said. AI, robotics and wearables The aging population stands to gain significantly from breakthroughs in robotics powered by artificial intelligence, according to Afzal. Arelis Agosto, research analyst at Global X ETFs, said wearables technology is one interesting area to invest in for the aging theme. "We view self-sustaining monitoring and therapeutic systems as the future of patient care, though it is particularly beneficial for elderly patients," Agosto said. Global X ETFs, a fund management company, offers a way to tap the aging theme through its Aging Population ETF.

Persons: Shams Afzal, There's, Afzal, Stryker, Dani Saurymper, Saurymper, Arelis Agosto, Agosto Organizations: Carnegie Investment, CNBC Pro, Stryker, EU, Longevity, Global, Carnegie, Abbott Laboratories, Agosto Locations: U.S, GLP, Agosto

☆ Johnson & Johnson forecasts as much as 6% sales growth in 2024
▼ + stars: | 2023-12-05 | by ( ) www.reuters.com time to read: +2 min

Dec 5 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. The company has narrowed its focus on its drugs and medical devices business since it hived off its consumer health unit earlier this year. Sales of blockbuster psoriasis treatment Stelara in Europe are expected to come under pressure as early as next year as a key patent on the drug expires. Sales of the drug largely come from its use as a treatment for inflammatory bowel diseases (IBD), Wolk said. J&J's 2024 revenue growth forecast excludes sales of its COVID vaccine.

Persons: Johnson, Joseph Wolk, Wolk, J, Bhanvi, Patrick Wingrove, Anil D'Silva Organizations: Johnson, Thomson Locations: Europe, United States, Bengaluru, New York

☆ Raymond James sees 'mild' recession, single digit stock return next year
▼ + stars: | 2023-11-30 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

Raymond James is bracing for a "mild" recession in the new year that will likely result in only "modest positive gains" for equities in 2024. "Single Digit Returns A Decent Base Case," he added. In Raymond James' base case scenario, or what it believes is the most likely assumption, McCourt said that corporate profit expectations likely need to come down. Heading into the new year, Raymond James favors several stock sectors, among them medical devices, financial services and insurance issues. In its base case scenario, real estate, utilities and telecom offer the best risk-reward.

Persons: Raymond James, Tavis McCourt, McCourt, — CNBC's Michael Bloom Organizations: Nasdaq

☆ Wall St ends lower amid Cyber Monday madness
▼ + stars: | 2023-11-27 | by ( Stephen Culp | ) www.reuters.com time to read: +5 min

Remarks from Federal Reserve policymakers later in the week will also be parsed for clues regarding the duration of the central bank's restrictive policy. Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 27, 2023. Amid the Cyber Monday fervor, Affirm Holdings (AFRM.O) surged 12.0%, as the payment platform's "buy now, pay later" option was seen hitting an all-time high, boosting the online holiday sales. Declining issues outnumbered advancing ones on the NYSE by a 1.25-to-1 ratio; on Nasdaq, a 1.63-to-1 ratio favored decliners. The S&P 500 posted 38 new 52-week highs and no new lows; the Nasdaq Composite recorded 84 new highs and 79 new lows.

Persons: Elliott, Tom Hainlin, Greg Bassuk, Brendan McDermid, they’ve, Hainlin, Shopify, Stephen Culp, Shristi Achar, Shinjini Ganguli, Matthew Lewis Organizations: Dow, Nasdaq, U.S, Bank Wealth Management, Adobe Analytics, AXS Investments, Federal Reserve, Financial, Commerce, New York Stock Exchange, REUTERS, Dow Jones, Elliott Investment Management, GE HealthCare, NYSE, Thomson Locations: Minneapolis, New York, New York City, U.S, Bengaluru

☆ Wall St pauses amid Cyber Monday madness; data, Fed speakers on tap
▼ + stars: | 2023-11-27 | by ( Stephen Culp | ) www.reuters.com time to read: +4 min

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 27, 2023. The tech-heavy Nasdaq was slightly higher, the Dow was edging red and the S&P 500 was essentially unchanged, but leaning lower. The S&P 500 Retail index (.SPXRT) was up 0.9%. Later in the week, market participants look to the Commerce Department's second take on third-quarter GDP expected on Wednesday, to be followed on Friday with its broad-ranging Personal Consumption Expenditures (PCE) report. The S&P 500 posted 34 new 52-week highs and no new lows; the Nasdaq Composite recorded 78 new highs and 64 new lows.

Persons: Brendan McDermid, Elliott, Dow, Greg Bassuk, Bassuk, Shopify, Stephen Culp, Shristi Achar, Shinjini Ganguli, Matthew Lewis Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Adobe Analytics, AXS Investments, Federal Reserve, Financial, Commerce, Dow Jones, Walmart, Elliott Investment Management, GE HealthCare, NYSE, Thomson Locations: New York City, U.S, New York, Bengaluru

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 27, 2023. The rebound in equities in November has brought the S&P 500 (.SPX) close to its highest intra-day level this year. "We are headed for a mixed session today...maybe something like profit taking at the beginning and then just a leveling off."U.S. The S&P 500 retail sector (.SPXRT), housing Amazon, rose 0.5%. The S&P index recorded 7 new 52-week highs and no new lows, while the Nasdaq recorded 34 new highs and 18 new lows.

Persons: Brendan McDermid, Elliott, Peter Cardillo, Jerome Powell, advancers, Shristi Achar, Saumyadeb Chakrabarty Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Federal Reserve, Spartan Capital Securities, Walmart, Reuters, Fed, Dow Jones, Crown, Elliott Investment Management, GE HealthCare, UBS, NYSE, Thomson Locations: New York City, U.S, Bengaluru

☆ Wall St futures edge lower as investor await data, policy cues
▼ + stars: | 2023-11-27 | by ( ) www.reuters.com time to read: +2 min

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 27, 2023. Wall Street ended the Thanksgiving week on a positive note, with the major indexes notching up their fourth consecutive week of gains on growing optimism that the Federal Reserve was likely done hiking interest rates. ET, Dow e-minis were down 48 points, or 0.14%, S&P 500 e-minis were down 7 points, or 0.15%, and Nasdaq 100 e-minis were down 23.75 points, or 0.15%. The personal consumption expenditure index data for October - the Fed's preferred inflation gauge - is slated to be released on Thursday. Reporting by Shristi Achar A and Shashwat Chauhan in Bengaluru; Editing by Saumyadeb ChakrabartyOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Axel Rudolph, Shristi Achar, Shashwat Chauhan, Saumyadeb Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Federal Reserve, Dow e, IG Group, Walmart, Crown, Elliott Investment Management, Reuters, GE HealthCare, UBS, Thomson Locations: New York City, U.S, Bengaluru

☆ A 27-year-old who built a side hustle 3D printing products to sell on Etsy did $10,000 in sales in one week. He explains the steps he took before coming up with bestselling product ideas.
▼ + stars: | 2023-11-26 | by ( Kathleen Elkins | ) www.businessinsider.com time to read: +8 min

That's when he listed what would become his next best-selling product: a gas can ornament with a compartment for stashing cash. He built seller credibility by listing inexpensive products to drive sales and reviewsWhen the first product Ziegler listed — the battery cases — didn't sell, he shifted his strategy. Ziegler's first product that hit: a travel soap box. Instead of abandoning the idea, Ziegler thought about ways he could make his product stand out. Now that he has a handful of bestselling items, though, "I'm doing a lot more Etsy fulfillment and a lot less design."

Persons: Austin Ziegler, Ziggy Zig, he's, — he's, Ziegler, I'm, It's, He's Organizations: Ziggy Zig Designs, Business Locations: Hawaii

☆ A 27-year-old who brings in up to $16,000 a month 3D printing ornaments and other products explains how he built a side hustle selling on Etsy
▼ + stars: | 2023-11-22 | by ( Kathleen Elkins | ) www.businessinsider.com time to read: +8 min

The very first product Ziegler listed for sale fell into the latter category. "So then I started just 3D printing products and trying to sell them on Etsy." Ziegler started his 3D printing business, Ziggy Zig Designs, with two Prusa printers and filament. He also bought 3D printing filament and downloaded a design software called SolidWorks . He shipped two more 3D printers to his place in Portland and cut his trip short to assemble the printers and start fulfilling orders.

Persons: Austin Ziegler, Ziegler, " Ziegler, Zig, Rollo, I'm, Etsy, Long Organizations: Business, YouTube Locations: Portland, Hawaii, Spokane , Washington

☆ Medical device maker Medtronic raises fiscal 2024 profit view
▼ + stars: | 2023-11-21 | by ( ) www.reuters.com time to read: +1 min

Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. Medtronic joins medical device makers including Abbott Laboratories (ABT.N) and Boston Scientific(BSX.N) that have benefited from soaring demand for non-urgent surgeries. It now expects profit to be between $5.13 per share and $5.19 per share for the fiscal year 2024, above the range of $5.08 per share to $5.16 per share expected previously. On an adjusted basis, the Dublin-based company reported a profit of $1.25 per share for the second quarter, above analysts' average estimate of $1.18 per share, according to LSEG data. Reporting by Khushi Mandowara and Christy Santhosh in Bengaluru; Editing by Pooja DesaiOur Standards: The Thomson Reuters Trust Principles.

Persons: Dado Ruvic, Medtronic, Khushi Mandowara, Christy Santhosh, Pooja Desai Organizations: REUTERS, Abbott, Abbott Laboratories, Boston, Thomson Locations: Dublin, Bengaluru

CNN —American Airlines said it is reviewing a video posted on TikTok that shows a baggage handler releasing a passenger’s wheelchair to slide down a jet bridge chute, where it crashed into a metal barrier, flipped over and tumbled onto an airport tarmac. In the video, as the first man lets the wheelchair go, a second baggage handler, who is on the ground at the other end of the chute and wearing an American Airlines vest, steps back. American Airlines said in a statement, “We recognize how important it is to support the independence of customers with disabilities by ensuring the proper care of mobility devices throughout their journey with us. In 2022, American Airlines’ rate of damaging, delaying or losing wheelchairs and scooters was 2.00 per 100, DOT statistics show. It also calls on the agency to study whether it is possible for passengers to use wheelchairs in the main cabin.

Persons: Haeley Dyrdahl, Dyrdahl, ”, “, Pete Buttigieg, Sen, Tammy Duckworth, ” Duckworth, “ It’s, Duckworth, John Thune, –, Steve Cohen, Pete Stauber, CNN’s David Williams, Ross Levitt, Gregory Wallace Organizations: CNN — American Airlines, Miami International Airport, CNN, American Airlines, Transportation, Department of Transportation, DOT, United Airlines, Illinois Democrat, Republican, Senate Commerce, Science, ”, Tennessee Democrat, Minnesota Republican Locations: America, American, Illinois, South Dakota, Tennessee, Minnesota

☆ Can you hack your brain? These companies are driving innovation in the field of brain stimulation
▼ + stars: | 2023-11-21 | by ( Pia Singh | ) www.cnbc.com time to read: +12 min

These forms of deep brain stimulation require a surgical procedure during which electrodes — which generate electrical impulses to control any abnormal brain activity — are implanted into certain areas of the brain. With enough advancement in the field, doctors expect brain stimulation techniques for both severe disorders and health-and-wellness purposes will ultimately become noninvasive. Three major players There are only three companies with FDA-approved deep brain stimulation, or DBS, treatments: Medtronic , Abbott Laboratories and Boston Scientific . The spinal cord stimulation, or SCS, business is a hotbed of innovation right now, deep brain stimulation also is a key area." There is still plenty of doubt, however, about the efficacy of at-home brain stimulation devices, which offer a less direct approach to brain stimulation and don't always require FDA oversight.

Persons: —, Bernstein, Lee Hambright, Hambright, Ali Rezai, Medtronic, Abbott, Rezai, Morningstar, Debbie Wang, Wang, Elon Musk, it's Elon Musk's, Casey Halpern, it's, Halpern, Taiwan's Organizations: Drug Administration, FDA, Abbott Laboratories, Boston, Rockefeller Neuroscience, West Virginia University, American Neuromodulation Society, Boston Scientific, DBS, FactSet, Neuroscience, BCI, University of Pennsylvania, TMS Locations: neuromodulation

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

☆ Cramer says mergers and acquisitions could be the ‘potential savior’ for much of the market
▼ + stars: | 2023-11-20 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

"Mergers and acquisitions could be the potential savior for much of this market, everything from medical devices to industrials, to retailers, aerospace, utilities, foods and drugs and so many other groups," he said. Cramer conceded that it has been a hard year for stocks other than those in the "Magnificent Seven," whose success has outshone most other sectors. Cramer said the possible solution for the rest of the market isn't necessarily about challenging the "Magnificent Seven," but changing the percentage gain of other companies. Cramer instead suggested mergers could lead to major gains in a variety of different sectors. "But given his pro-worker attitude and the fact that mergers often lead to layoffs, I doubt he'll go there.

Persons: CNBC's Jim Cramer, Cramer, he's, Joe, Biden, Lina Khan, he'll Organizations: Federal Trade Commission, Nasdaq, Meta, Microsoft, Nvidia, Tesla

☆ Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
▼ + stars: | 2023-11-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Makers of medical devices were prepared for doom and gloom following a study of obesity drugs and cardiovascular health—but the bearish scenario hasn’t panned out. Photo: Catherine Ivill/Getty ImagesThere is a bit of cognitive dissonance in healthcare investing right now. After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.

Persons: Catherine Ivill, Novo, Wegovy, ” gushed Evan Seigerman Organizations: pharma, BMO Capital Markets

The Energy Department is making a push to strengthen the U.S. battery supply chain, announcing up to $3.5 billion for companies that produce batteries and the critical minerals that go into them. Some officials, industry experts and others concerned about climate change uneasy supply of battery materials will not keep pace with demand. The Bipartisan Infrastructure Law assigned $6 billion in total funding for battery material processing and manufacturing. An initial round went to 15 projects including companies that mine critical minerals like graphite and nickel, used in lithium batteries. Tom Moerenhout, a professor at Columbia University's Center on Global Energy Policy, said it will be a big challenge to ramp up the global supply of critical minerals for the projected battery demand in 2030.

Persons: Harris, Jodie Lutkenhaus, “ I’m, ”, ” Lutkenhaus, Matthew McDowell, Tom Moerenhout, “, Moerenhout Organizations: Energy Department, DOE, Biden, Texas, M University, Infrastructure Law, Georgia Institute of Technology, Columbia University's Center, Global Energy, Companies, ____, AP Locations: Asia, Albemarle, Kings Mountain , North Carolina, U.S

Search resuls for: "Medical Devices"

25 mentions found